Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer

FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.

Cancer Currents: An NCI Cancer Research Blog